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The COVID-19 pandemic is a major threat to global health1 for which there are limited 
medical countermeasures2,3. Moreover, we currently lack a thorough understanding 
of mechanisms of humoral immunity4. From a larger panel of human monoclonal 
antibodies (mAbs) targeting the spike (S) glycoprotein5, we identified several that 
exhibited potent neutralizing activity and fully blocked the receptor-binding domain 
of S (SRBD) from interacting with human ACE2 (hACE2). Competition-binding, 
structural, and functional studies allowed clustering of the mAbs into classes 
recognizing distinct epitopes on the SRBD as well as distinct conformational states of 
the S trimer. Potent neutralizing mAbs recognizing non-overlapping sites, COV2-2196 
and COV2-2130, bound simultaneously to S and synergistically neutralized authentic 
SARS-CoV-2 virus. In two mouse models of SARS-CoV-2 infection, passive transfer of 
either COV2-2196 or COV2-2130 alone or a combination of both mAbs protected mice 
from weight loss and reduced viral burden and inflammation in the lung. In addition, 
passive transfer of each of two of the most potently ACE2 blocking mAbs (COV2-2196 
or COV2-2381) as monotherapy protected rhesus macaques from SARS-CoV-2 
infection. These results identify protective epitopes on SRBD and provide a 
structure-based framework for rational vaccine design and the selection of r ob ust 
i mm unotherapeutics.
The S protein of SARS-CoV-2 is the molecular determinant of viral 
attachment, fusion, and entry into host cells6. The S protein is com-
posed of an N-terminal subunit (S1) that mediates receptor binding 
and a C-terminal subunit (S2) that mediates virus–cell membrane 
fusion. The S1 subunit contains an N-terminal domain (NTD) and a 
receptor-binding domain (RBD). SARS-CoV-2 and SARS-CoV, which 
share approximately 78% sequence identity in their genomes1 both 
use human angiotensin-converting enzyme 2 (hACE2) as an entry 
receptor7–9. Human Abs to the (S) glycoprotein mediate protective 
immunity against other high-pathogenicity zoonotic betacoronavi-
ruses including SARS-CoV10–14 and Middle East respiratory syndrome 
(MERS)15–24. The most potent S protein-specific mAbs appear to 
neutralize betacoronaviruses by blocking attachment of virus to host 
cells by binding to the region on SRBD that directly mediates receptor 
engagement. It is likely that human Abs have promise for modifying 
disease, when used for prophylaxis, post-exposure prophylaxis, or 
treatment of SARS-CoV-2 infection25. Many studies are ongoing, includ-
ing randomized controlled trials evaluating convalescent plasma and 
one trial evaluating hyperimmune immunoglobulin, but it is not yet 
clear whether such treatments can reduce morbidity or mortality26.
We isolated a large panel of SARS-CoV-2 S protein-reactive mAbs 
from the B cells of two convalescing individuals who had been infected 
with SARS-CoV-2 in Wuhan China5. A subset of those antibodies bound 
to a recombinant RBD construct (SRBD) and exhibited neutralizing 
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activity in a rapid screening assay with authentic SARS-CoV-25. Here, 
we defined the antigenic landscape of SARS-CoV-2 and determined 
which sites of SRBD are targets of neutralizing mAbs. We tested a panel 
of 40 anti-S human mAbs we previously pre-selected by a rapid neu-
tralization screening assay in a quantitative focus reduction neutrali-
zation test (FRNT) with SARS-CoV-2 strain WA1/2020. These assays 
revealed the panel exhibited a range of half-maximal inhibitory con-
centration (IC50) values, from 15 to over 4,000 ng/mL (visualized as 
a heatmap in Fig. 1a, values shown in Supplemental Table 1, and full 
curves shown in Extended Data Fig. 1). We hypothesized that many of 
these SRBD-reactive mAbs neutralize virus infection by blocking SRBD 
binding to hACE2. Indeed, most neutralizing mAbs we tested inhib-
ited the interaction of hACE2 with trimeric S protein directly (Fig. 1a; 
Extended Data Fig. 2). Consistent with these results, these mAbs also 
bound strongly to a trimeric S ectodomain (S2Pecto) protein or mono-
meric RBD SRBD (Fig. 1a; Extended Data Fig. 3). We evaluated whether 
S2Pecto or SRBD binding or hACE2-blocking potency predicted binding 
neutralization potency independently, but none of these measure-
ments correlated with neutralization potency (Fig. 1b–d). However, 
each of the highest neutralizing potency tier (IC50<150 ng/mL) also had 
the strongest blocking activity against hACE2 (IC50< 150 ng/mL) and 
exceptional binding activity (EC50< 2 ng/mL) to S2Pecto trimer (Fig. 1e). 
Representative neutralization curves for two potently neutralizing 
mAbs designated COV2-2196 and COV2-2130 are shown in Fig. 1f. Potent 
neutralization was confirmed using pseudovirus neutralization assays, 
which revealed far more sensitive neutralization phenotypes than wt 
virus and demonstrated a requirement for the use of live virus assays 
for assessment of mAb potency (Fig. 1g). Both of these mAbs bound 
strongly to S2Pecto trimer and fully blocked hACE2 binding (Fig. 1h, i).
We next defined the major antigenic sites on SRBD for neutraliz-
ing mAbs by competition-binding analysis. We first used a biolayer 
interferometry-based competition assay with a minimal SRBD domain 
to screen for mAbs that competed for binding with the potently neu-
tralizing mAb COV2-2196 or a recombinant version of the previously 
described SARS-CoV mAb CR3022, which recognizes a conserved 
cryptic epitope12,27. We identified three major groups of competing 
mAbs (Fig. 2a). The largest group of mAbs blocked COV2-2196 but not 
rCR3022, while some mAbs were blocked by rCR3022 but not COV2-
2196. Two mAbs, including COV2-2130, were not blocked by either refer-
ence mAb. Most mAbs competed with hACE2 for binding, suggesting 
that they bound near the hACE2 binding site of the SRBD. We used COV2-
2196, COV2-2130, and rCR3022 in an ELISA-based competition-binding 
assay with trimeric S2Pecto protein and also found that SRBD contained 
three major antigenic sites, with some mAbs likely making contacts in 
more than one site (Fig. 2b). Most of the potently neutralizing mAbs 
directly competed for binding with COV2-2196. The hACE2 and mAb 
competition binding analysis with SARS-CoV-2 convalescent patient 
serum or plasma from four previously described immune subjects5 
showed that COV2-2196- and COV2-2130-like antibody responses are 
subdominant in these subjects (Extended Data Fig. 4).
Since COV2-2196 and COV2-2130 did not compete for binding to 
SRBD, we assessed if these mAbs synergize for virus neutralization, a 
phenomenon previously observed for SARS-CoV mAbs12. We tested 
combination responses (Fig. 2c) in the FRNT using SARS-CoV-2 and 
compared these experimental values with the expected responses 
calculated by synergy scoring models28. The comparison revealed that 
the combination of COV2-2196 + COV2-2130 was synergistic (Fig. 2d) 
(with a synergy score of 17.4, where any score of >10 indicates synergy). 
In particular, combined mAb dose of 79 ng/mL in the cocktail (16 ng/
mL of COV2-2196 and 63 ng/mL of COV2-2130) had the same activity 
as 250 ng/mL of each individual mAb (Fig. 2c). This finding shows that 
by using a cocktail the dose of each mAb can be reduced by more than 
three-fold to achieve the same potency of virus neutralization in vitro.
We next defined the epitopes recognized by representative mAbs 
in the two major competition-binding groups that synergize for 
neutralization. We determined critical residues for binding of neutral-
izing mAbs using mutagenesis. (Fig. 3a, Extended Data Fig. 5). These 
studies revealed F486A or N487A as critical residues for COV2-2196 
and N487A as a critical residue for COV2-2165, which compete with one 
another for binding. Likewise, mutagenesis studies for COV2-2130 using 
K444A and G447R mutants defined these residues as critical for recog-
nition (Fig. 3a). Previous structural studies have defined the interaction 
between the SRBD and hACE2
29 (schematic shown in Fig. 3b). Most of the 
interacting residues in the SRBD are contained within a 60-amino-acid 
linear peptide that defines the hACE2 recognition motif (Fig. 3c). We 
next tested binding of human mAbs to this minimal peptide and found 
that potent neutralizing members of the largest competition-binding 
group including COV2-2196, COV2-2165, and COV2-2832 recognized 
this peptide (Fig. 3c), suggesting these mAbs make critical contacts 
within the hACE2 recognition motif.
We used negative-stain electron microscopy (NS-EM) of S2Pecto 
trimer/Fab complexes to determine the structural epitopes for sev-
eral mAbs (Fig. 3d, e, Supplemental Table 2). The potently neutralizing 
antibodies COV2-2196 and COV2-2165 bound the hACE2 recognition 
motif of SRBD and recognized the ‘open’ conformational state of the 
S2Pecto trimer, in which the RBD rotates upward to expose the residues 
that mediate ACE2 interaction (Fig. 3d)30,31. COV2-2130, which rep-
resents a different competition-binding group, bound to the RBD in 
the S2Pecto trimer in the ‘closed’ position (Fig. 3d). Since COV2-2196 
and COV2-2130 did not compete for binding, we attempted to make 
complexes of both Fabs bound at the same time to the S2Pecto trimer. 
We found that both Fabs bound simultaneously when the S2Pecto trimer 
was in the open position, indicating that COV2-2130 can recognize the 
SRBD in both conformations (Fig. 3e). Overlaying the two-Fab complex 
with the structure of the RBD:CR3022 complex27, we observed that 
these antibodies bind to three distinct sites on SRBD, as predicted by 
our competition-binding studies (Fig. 3f).
Next, we tested the prophylactic efficacy of COV2-2196 or COV2-2130 
monotherapy or a combination of COV2-2196 + COV2-2130 in a newly 
developed SARS-CoV-2 infection model in BALB/c mice. In this model (as 
diagrammed in Fig. 4a), mice are first administered anti-Ifnar1 antibody 
and then transduced with adenovirus-expressing hACE2 (AdV-hACE2) 
that results in susceptibility to infection with SARS-CoV-2, viral repli-
cation, and severe bronchopneumonia32. In the present experiments, 
these mice were passively transferred a single dose of mAb COV2-2196, 
COV2-2130, a cocktail of COV2-2196 + COV2-2130, or an isotype control 
mAb one day before intranasal challenge with SARS-CoV-2 (4 x 105 PFU). 
Prophylaxis with COV2-2196 or COV2-2130 or their combination attenu-
ated severe SARS-CoV-2-induced weight loss through the first week of 
infection (Fig. 4b). Viral RNA levels were reduced significantly at 7 dpi in 
the lung and distant sites including the heart and spleen (Fig. 4c). The 
expression of cytokine and chemokine genes indicative of inflammation 
was also reduced in the lungs of each group of COV-antibody-treated 
mice at 7 dpi (Fig. 4d).
We also tested COV2-2196 or COV2-2130 or their combination 
for prophylactic efficacy in an immunocompetent model using a 
mouse-adapted (MA) SARS-CoV-2 virus33 (Fig. 4e, f). Each of the mAb 
treatments reduced viral RNA levels up to 105-fold at 2 dpi in the lung 
when compared to the isotype control group (Fig. 4f, left). All animals 
from COV2-2196 and COV2-2196 + COV2-2130 treatment group and 
8 of 10 animals from COV2-2130 treatment no longer had infectious 
virus at 2 dpi in the lung as measured by plaque assay of lung tissue 
homogenates (Fig. 4f, right).
We evaluated the impact of mAb treatment on SARS-CoV-2-induced 
lung pathology. At 7 dpi, lungs from Ifnar1-antibody-treated–
AdV-hACE2-transduced that were treated with isotype mAb and then 
infected with SARS-CoV-2- showed perivascular, peribronchial, and 
alveolar inflammation with immune cell infiltration and alveolar dam-
age that are characteristic of viral pneumonia (Fig. 4g; Supplemen-














instead with COV2-2196 or COV2-2130 or the combination of these 
mAbs developed significantly less lung disease, which was similar to 
that observed in AdV-hACE2-transduced control mice that were not 
infected with SARS-CoV-2 (Fig. 4g; Supplemental Table 3).
We next tested the protective efficacy of mAbs using a recently 
described SARS-CoV-2 non-human primate (NHP) challenge model34,35. 
For this model, we tested as monotherapy COV2-2196 and another of 
the most potent antibodies identified, COV2-2381, a neutralizing mAb 
encoded by the same variable gene segments as COV2-2196 but with a 
number of amino acid differences in the HCDR3 and LCDR3 (Extended 
Data Fig. 6a). Importantly, others have identified highly similar mAbs 
from multiple donors, demonstrating that these mAbs constitute 
a public clonotype36. Animals received one 50 mg/kg dose of mAb 
COV2-2196 or mAb COV2-2381 or isotype control mAb intravenously 
on day -3 and then were challenged intranasally and intratracheally 
on day 0 with a dose of 1.1 × 104 PFU SARS-CoV-2. Following challenge, 
we quantified subgenomic viral RNA generated by viral replication 
using RT-qPCR in bronchoalveolar lavage (BAL) and nasal swabs. High 
levels of subgenomic viral RNA were observed in the isotype control 
mAb-treated NHPs, with a median peak of 7.53 (range 5.37 to 8.23) log10 
RNA copies/swab in nasal swab and a median peak of 4.97 (range 3.81 
to 5.24) log10 RNA copies/mL in BAL (Fig. 4h, i). Subgenomic viral RNA 
was not detected in samples from either of the mAb treatment groups 
(LOD = 50 [1.7 log10] RNA copies/swab or per mL) showing protection. 
A pharmacokinetics analysis revealed similar concentrations of cir-
culating human mAbs in NHPs from each treatment group (Extended 
Data Fig. 6b).
We next assessed the therapeutic efficacy of treatment by COV2-
2196 or COV2-2130 or their combination using the MA-SARS-CoV-2 
challenge model. All treatments reduced infectious virus at 2 dpi in the 
lung. The cocktail (1:1) delivered at a dose of 400 µg/mouse (~ 20 mg/
kg) was the most efficient, as it significantly reduced lung burden up 
to 3 x 104-fold; 4 of 5 animals from this treatment group did not have 
detectable infectious virus in the lung (Fig. 5a). Similarly, treatment 
of AdV-hACE2-transduced mice with 400 µg/mouse of the cocktail 
12 hrs after authentic SARS-CoV-2 challenge revealed full neutralization 
of infectious virus in the lungs in vivo (Fig. 5b). Inflammation also was 
reduced in the lungs of mAb cocktail-treated mice when compared 
to the lungs of isotype-control-treated mice (Fig. 5c). Collectively, 
these in vivo results suggest that either of the potently neutralizing 
mAbs COV2-2196 or COV2-2381 alone or COV2-2196 and COV2-2130 in 
combination are promising candidates for prevention or treatment 
of COVID-19.
Since the start of the SARS-CoV-2 pandemic, several groups have iden-
tified human mAbs that bind the RBD and neutralize virus36–44. Here, we 
defined the antigenic landscape for a number of potently neutralizing 
mAbs against SARS-CoV-2 derived from a larger panel of hundreds5. 
These studies demonstrate that although diverse human neutralizing 
antibodies are elicited by natural infection with SARS-CoV-2, only a 
small subset of those mAbs are of high potency (IC50<50 ng/mL against 
authentic SARS-CoV-2 virus). Biochemical and structural analysis of 
these potent mAbs defined three principal antigenic sites of vulner-
ability on the SRBD for SARS-CoV-2 neutralization. Representative mAbs 
from two antigenic sites were shown to synergize in vitro and protect 
as an in vivo cocktail in both prophylactic and therapeutic treatment. 
Our findings reveal critical features of effective humoral immunity 
to SARS-CoV-2 and suggests that the role of synergistic neutraliza-
tion activity in polyclonal responses should be explored. Moreover, 
as SARS-CoV-2 continues to circulate, population immunity elicited by 
natural infection may start to select for antigenic variants that escape 
from the selective pressure of neutralizing antibodies. Other groups 
have reported selecting SARS-CoV-2 RBD escape mutations in the pres-
ence of single mAbs but not in the presence of a mixture of two mAbs45, 
reinforcing the need to target multiple epitopes of S in vaccines or 
immunotherapies. To date, the S gene has limited diversity with the 
exception of a D614G substitution46, far away from the amino acid posi-
tions identified in our mutational studies for the mAbs studied here. 
Rationally-selected therapeutic cocktails like the one described here 
likely offer greater resistance to SARS-CoV-2 escape. These studies 
set the stage for preclinical evaluation and development of the identi-
fied mAbs as candidates for use as COVID-19 immunotherapeutics in 
humans.
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Fig. 1 | Functional characteristics of neutralizing SARS-CoV-2 mAbs.  
a. Heatmap of mAb neutralization activity, hACE2 blocking activity, and 
binding to either trimeric S2Pecto protein or monomeric SRBD. MAbs are ordered 
by neutralization potency, and dashed lines indicate the 12 antibodies with a 
neutralization IC50 value lower than 150 ng/mL. IC50 values are visualized for 
viral neutralization and hACE2 blocking, while EC50 values are visualized for 
binding. The cross-reactive SARS-CoV SRBD mAb rCR3022 is shown as a positive 
control, while the anti-dengue mAb r2D22 is shown as a negative control. Data 
are representative of at least 2 independent experiments performed in 
technical duplicate. No inhibition or no binding indicates an IC50 or EC50 value 
of >10,000 ng/mL, respectively. b-d. Correlation of hACE2 blocking, S2Pecto
trimer binding, or SRBD binding of mAbs with their neutralization activity. 
e. Correlation of hACE2 blocking and S2Pecto trimer binding. R2 values are 
shown for linear regression analysis of log-transformed values. Purple circles 
indicate mAbs with a neutralization IC50 value lower than 150 ng/mL. 
f. Neutralization curves for COV2-2196 and COV2-2130 against authentic 
SARS-CoV-2 virus. Calculated IC50 values are denoted on the graph. Error bars 
denote the standard deviation of each point. Data are representative of at least 
2 independent experiments, each performed in technical duplicate. 
g. Neutralization curves for COV2-2196 and COV2-2130 in a pseudovirus 
neutralization assay. Error bars denote the standard deviation of each point. 
Values shown are technical duplicates from a single experiment. Calculated 
IC50 values from a minimum of 6 experiments are denoted on the graph. 
h. hACE2 blocking curves for COV2-2196, COV2-2130, and the non-blocking 
SARS-CoV mAb rCR3022 in the hACE2 blocking ELISA. Calculated IC50 values 
are denoted on the graph.. Mean ± SD of technical triplicates are shown from a 
representative experiment repeated twice. i. ELISA binding of COV2-2196, 
COV2-2130, and rCR3022 to trimeric S2Pecto. Calculated EC50 values are denoted 
on the graph. Mean ± SD of technical triplicates are shown from a 












Fig. 2 | Epitope mapping of mAbs by competition-binding analysis and 
synergistic neutralization by a pair of mAbs. a. Left: mAb binding to RBD in 
presence of reference mAbs COV2-2196 and rCR3022. Values in squares are % 
binding of the mAb in the presence of the competing mAb relative to a 
mock-competition control. Black squares denote full competition (<33% 
relative binding), while white squares denote no competition (>67% relative 
binding). Right: biolayer interferometry-based competition binding assay 
measuring the ability of mAbs to prevent binding of hACE2. Values denote % 
blocking of hACE2 by mAb. Red color denotes high blocking activity.  
b. Competition of neutralizing mAb panel with reference mAbs COV2-2130, 
COV2-2196, or rCR3022. Binding of reference mAbs to trimeric S2Pecto was 
measured in the presence of saturating competitor mAb in a competition ELISA 
and normalized to binding in the presence of the anti-dengue mAb r2D22. Black 
denotes full competition (<25% binding of reference mAb), grey denotes partial 
competition (25-60% binding of reference mAb), and white denotes no 
competition (>60% binding of reference mAb). c. Neutralization dose-response
matrix of wild-type SARS-CoV-2 by COV2-2196 and COV2-2130. Axes denote the 
concentration of each mAb with % neutralization shown in each square. Data is 
from a representative experiment that was performed in technical triplicate 
and repeated twice. A white-to-red heatmap denotes 0% neutralization to 100% 
neutralization, respectively. d. Synergy map calculated based on the 
SARS-CoV-2 neutralization in c. Red color denotes areas where synergistic 
neutralization was observed, and a black box denotes the area of maximal 














Fig. 3 | Epitope identification and structural characterization of mAbs.  
a. Identification of critical contact residues by alanine and arginine 
mutagenesis. Top: binding of COV2-2130 (gold), COV2-2165 (maroon) or COV2-
2196 (dark purple) to wild-type (wt) or mutant SRBD constructs normalized to wt. 
Bottom: representative binding curves for COV2-2196 to wt or SRBD constructs
with mutated critical contact residues. b. Co-crystal structure of SARS-CoV-2 
RBD (blue) and hACE2 (green) (PDB 6M0J). The hACE2 recognition motif is 
colored orange. Critical contact residues are shown for COV2-2130 (gold 
spheres) and COV2-2196 (purple spheres). c. ELISA binding of mAbs to the 
hACE2 recognition motif. r2D22 is shown as a negative control. Mean ± SD of 
technical triplicates are shown from a single experiment repeated twice. 
Bottom: structure of hACE2 recognition motif in orange with COV2-2196 
critical contact residues shown in purple. d. Single-Fab:S2Pecto trimer 
complexes visualized by negative-stain electron microscopy for COV2-2130 
(gold), COV2-2165 (maroon), or COV2-2196 (dark purple). The RBD is shown in 
blue and the S N-terminal domain (NTD) is shown in red. Electron density is 
shown in grey. Trimer state (open or closed) is denoted for each complex. 
Representative 2D class averages for each complex are shown at the bottom 
(box size is 128 pixels, with 3.06 Å/pixel). Data were collected in a single 
experiment with detailed collection statistics in Supplemental Table 2.  
e. COV2-2130 and COV2-2196 Fabs in complex with S2Pecto trimer. Colors and 
data collection are as in (d). Representative 2D class averages for the complexes 
are shown at the bottom with scales as in (d). f. Competition-binding analysis
visualized on S2Pecto trimer. The CR3022 crystal structure was docked into the 
double-Fab:S2Pecto trimer model. CR3022 is shown in cyan. Bottom: a 















Fig. 4 | Prophylactic efficacy of neutralizing human mAbs against 
SARS-CoV-2 infection in mouse and NHP models in vivo. a. SARS-CoV-2 
challenge model. Mice were treated with anti-Ifnar1 mAb, transduced with 
AdV-hACE2, and 200 µg of mAbs COV2-2196, -2130, or combination (1:1 ratio) or 
isotype control mAb were passively transferred. One day later, SARS-CoV-2 was 
inoculated via the i.n. route. Tissues were harvested at 7 dpi for analysis (c, d).  
b. Body weight change of mice in (a) with comparison to isotype control using a
repeated measurements two-way ANOVA with Tukey’s post-test. Mean ± SEM of 
each experimental group is shown. Numbers of animals (n) for each 
experimental group are shown. Viral burden in the lung, spleen and heart (c) 
and cytokine and chemokine gene expression (d) were measured by RT-qPCR 
assay. Comparisons were performed using a Kruskal-Wallis ANOVA with Dunn’s 
post-test. e. MA-SARS-CoV-2 challenge model. Mice were treated with indicated 
mAb and then infected intranasally with MA-SARS-CoV-2. Body weight change 
of mice is shown. Mean ± SEM of each experimental group is shown. f. Viral 
burden in the lung was measured at 2 dpi by RT-qPCR (left) or plaque assay 
(right) from (e); comparisons were made using a Kruskal-Wallis ANOVA with 
Dunn’s post-test. g. Hematoxylin and eosin staining of lung sections from mice 
that were treated and challenged as in (a). Images show low- (left), medium- 
(middle), and high-power magnification (right). Each image is representative of 
two separate experiments (n = 3 to 5 mice per group). h-i. SARS-CoV-2 NHP 
challenge model. Animals received one 50 mg/kg dose of mAb COV2-2196 (n = 4 
NHPs per group) or mAb COV2-2381 (n = 4 NHPs per group) or isotype mAb  
(n = 4 NHPs per group) served as a contemporaneous control intravenously on 
day -3 and then challenged intranasally and intratracheally with SARS-CoV-2 in 
three days. Subgenomic viral RNA levels were assessed in nasal swabs (h) and 
the bronchioalveolar lavage (i) at multiple timepoints following challenge. 
Each black curve shows an individual animal, with red lines indicating the 
median values of animals within each treatment group. Data represent a single 













Fig. 5 | Therapeutic efficacy of neutralizing human mAbs against 
SARS-CoV-2 infection. a. Mice were inoculated via the i.n. route with 
MA-SARS-CoV-2 and 12 hrs later given the indicated mAb treatments by i.p. 
injection. Viral burden in the lungs was measured by plaque assay. Number of 
mice per group (n) is indicated, and data represent one experiment. b. Mice 
were treated with anti-Ifnar1 mAb and transduced with AdV-hACE2. Mice were 
then inoculated via the i.n. route with SARS-CoV-2 and given the indicated mAb 
treatments by i.p. injection 12 hrs later. Two experiments were performed with 
3 to 5 mice per group. Viral burden in the lungs was measured by plaque assay. 
Controls for plaque neutralization assay performance were included: lung 
homogenates from individual (n = 3) isotype-control-mAb-treated mice were 
mixed 1:1 (v:v) with lung homogenates from individual naïve untreated mice or 
mAb cocktail-treated mice. The latter mixture ensures that neutralization of 
infection did not occur ex vivo after tissue homogenization. For (a) and (b) 
measurements from individual mice and median titer are shown, and each 
group was compared to the isotype-control-treated group using a 
Kruskal-Wallis ANOVA with Dunn’s post-test. c. Cytokine and chemokine gene 
expression was measured by qPCR analysis from the lungs harvested as in (b). 
Measurements from individual mice and median values are shown. Groups 
were compared using the two-sided Mann-Whitney U test. Number of mice per 
















The human antibodies studied in this paper were isolated from 
blood samples from two subjects in North America with previous 
laboratory-confirmed symptomatic SARS-CoV-2 infection that was 
acquired in China. The original clinical studies to obtain specimens after 
written informed consent were previously described5 and had been 
approved by the Institutional Review Board of Vanderbilt University 
Medical Center, the Institutional Review Board of the University of 
Washington, and the Research Ethics Board of the University of Toronto. 
The subjects (a 56-year-old male and a 56-year-old female) are a mar-
ried couple and residents of Wuhan, China who traveled to Toronto, 
Canada, where PBMCs were obtained by leukopheresis 50 days after 
symptom onset. The antibodies were isolated using diverse tools for 
isolation and cloning of single antigen-specific B cells and the antibody 
variable genes encoding monoclonal antibodies5.
Cell culture
Vero E6 (American Type Culture Collection (ATCC), Cat# CRL-1586), 
Vero (ATCC Cat# CCL-81), HEK293 (ATCC Cat# CRL-1573), and HEK293T 
(ATCC Cat# CRL-3216) were maintained at 37 °C in 5% CO2 in Dulbec-
co’s minimal essential medium (DMEM) containing 10% (vol/vol) 
heat-inactivated fetal bovine serum (FBS), 10 mM HEPES pH 7.3, 1 mM 
sodium pyruvate, 1× non-essential amino acids, and 100 U/mL of penicil-
lin–streptomycin. Vero-furin cells were obtained from T. Pierson (NIH) 
and have been described previously47. FreeStyle 293F (ThermoFisher 
Scientific, R79007) were maintained at 37 °C in 8% CO2. Expi293F cells 
(ThermoFisher Scientific, A1452) were maintained at 37 °C in 8% CO2 
in Expi293F Expression Medium (ThermoFisher Scientific, A1435102). 
ExpiCHO cells (ThermoFisher Scientific, A29127) were maintained at 
37 °C in 8% CO2 in ExpiCHO Expression Medium (ThermoFisher Sci-
entific, A2910002). Mycoplasma testing of Expi293F and ExpiCHO 
cultures was performed on a monthly basis using a PCR-based myco-
plasma detection kit (ATCC, 30-1012K).
Viruses
SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 was obtained from the 
Centers for Disease Control and Prevention (a gift from Natalie Thorn-
burg). Virus was passaged in Vero CCL81 cells and titrated by plaque 
assay on Vero E6 cells. Mouse adapted SARS-CoV-2 (MA-SARS-CoV-2) 
virus was generated as described previously33. Virus was propagated 
in Vero E6 cells grown in DMEM supplemented with 10% Fetal Clone II 
and 1% Pen/Strep. Virus titer was determined by plaque assay. Briefly, 
virus was diluted serially and inoculated onto confluent monolayers of 
Vero E6 cells, followed by an agarose overlay. Plaques were visualized 
on day 2 post-infection after staining with neutral red dye. All work with 
infectious SARS-CoV-2 was approved by the Washington University 
School of Medicine or UNC-Chapel Hill Institutional Biosafety Com-
mittees and conducted in approved BSL3 facilities using appropriate 
powered air purifying respirators and personal protective equipment.
Recombinant antigens and proteins
A gene encoding the ectodomain of a prefusion conformation-stabilized 
SARS-CoV-2 spike (S2Pecto) protein was synthesized and cloned into 
a DNA plasmid expression vector for mammalian cells. A similarly 
designed S protein antigen with two prolines and removal of the furin 
cleavage site for stabilization of the prefusion form of S was reported 
previously30. Briefly, this gene includes the ectodomain of SARS-CoV-2 
(to residue 1,208), a T4 fibritin trimerization domain, an AviTag 
site-specific biotinylation sequence, and a C-terminal 8x-His tag. To 
stabilize the construct in the prefusion conformation, we included 
substitutions K986P and V987P and mutated the furin cleavage site 
at residues 682-685 from RRAR to ASVG. This recombinant spike 
2P-stabilized protein (designated here as S2Pecto) was isolated by metal 
affinity chromatography on HisTrap Excel columns (GE Healthcare), 
and protein preparations were purified further by size-exclusion chro-
matography on a Superose 6 Increase 10/300 column (GE Healthcare). 
The presence of trimeric, prefusion conformation S protein was veri-
fied by negative-stain electron microscopy5. For electron microscopy 
with S and Fabs, we expressed a variant of S2Pecto lacking an AviTag 
but containing a C-terminal Twin-Strep-tag, similar to that described 
previously30. Expressed protein was isolated by metal affinity chro-
matography on HisTrap Excel columns (GE Healthcare), followed by 
further purification on a StrepTrap HP column (GE Healthcare) and 
size-exclusion chromatography on TSKgel G4000SW XL (TOSOH). To 
express the SRBD subdomain of SARS-CoV-2 S protein, residues 319-541 
were cloned into a mammalian expression vector downstream of an IL-2 
signal peptide and upstream of a thrombin cleavage site, an AviTag, and 
a 6x-His tag. RBD protein fused to mouse IgG1 Fc domain (designated 
RBD-mFc), was purchased from Sino Biological (40592-V05H). For 
epitope mapping by alanine scanning, SARS-CoV-2 RBD (residues 334-
526) or RBD single mutation variants were cloned with an N-terminal 
CD33 leader sequence and C-terminal GSSG linker, AviTag, GSSG 
linker, and 8xHisTag. Spike proteins were expressed in FreeStyle 293 
cells (Thermo Fisher) or Expi293 cells (ThermoFisher) and isolated by 
affinity chromatography using a HisTrap column (GE Healthcare), fol-
lowed by size exclusion chromatography with a Superdex200 column 
(GE Healthcare). Purified proteins were analyzed by SDS-PAGE to ensure 
purity and appropriate molecular weights.
Electron microscopy (EM) stain grid preparation, imaging 
and processing of SARS-CoV-2 S2Pecto protein or S2Pecto/Fab 
complexes
To perform EM imaging, Fabs were produced by digesting recombi-
nant chromatography-purified IgGs using resin-immobilized cysteine 
protease enzyme (FabALACTICA, Genovis). The digestion occurred 
in 100 mM sodium phosphate, 150 mM NaCl pH 7.2 (PBS) for ~16 hrs at 
ambient temperature. In order to remove cleaved Fc and intact IgG, the 
digestion mix was incubated with CaptureSelect Fc resin (Genovis) for 
30 min at ambient temperature in PBS buffer. If needed, the Fab was 
buffer exchanged into Tris buffer by centrifugation with a Zeba spin 
column (Thermo Scientific).
For screening and imaging of negatively-stained (NS) SARS-CoV-2 
S2Pecto protein in complex with human Fabs, the proteins were incu-
bated at a molar ratio of 4 Fab:3 spike monomer for ~1 hr and approxi-
mately 3 µL of the sample at concentrations of about 10 to 15 µg/mL 
was applied to a glow discharged grid with continuous carbon film on 
400 square mesh copper EM grids (Electron Microscopy Sciences). 
The grids were stained with 0.75% uranyl formate (UF)48. Images were 
recorded on a Gatan US4000 4k × 4k CCD camera using an FEI TF20 (TFS) 
transmission electron microscope operated at 200 keV and control 
with SerialEM49. All images were taken at 50,000× magnification with 
a pixel size of 2.18 Å/pix in low-dose mode at a defocus of 1.5 to 1.8 µm. 
Total dose for the micrographs was ~25 to 38 e−/Å2. Image processing 
was performed using the cryoSPARC software package50. Images were 
imported, and particles were CTF estimated. The images then were 
denoised and picked with Topaz51. The particles were extracted with 
a box size of 256 pixels and binned to 128 pixels. 2D class averages 
were performed and good classes selected for ab-initio model and 
refinement without symmetry. For EM model docking of SARS-CoV-2 
S2Pecto protein, the closed model (PDB: 6VXX) was used in Chimera
52 
for docking to the EM map (see also Supplemental Table 2 for details). 
For the SARS-CoV-2 S2Pecto/Fab COV2-2165, SARS-CoV-2 S2Pecto/Fab 
COV2-2196, and SARS-CoV-2 S2Pecto/Fab COV2-2832 complexes, the 
open model of SARS-CoV-2 (PDB: 6VYB) and Fab (Fab: 12E8) was used 
in Chimera for docking to the EM maps (see also Supplemental Table 2 
for details). For the SARS-CoV-2 S2Pecto/Fab COV2-2130 complex, the 
closed model and Fab (PDB: 12E8) were used in Chimera for docking 














SARS-CoV-2 S2Pecto/Fab COV2-2096 complexes, both the open (PDB: 
6VYB) and closed (PDB: 6VXX) models were used. All images were 
made with Chimera. PyMOL (Schrödinger, Inc) was used to visual-
ize previously solved molecular structures of the SARS-CoV-2 RBD/
hACE2 complex and the 60-amino-acid hACE2 recognition motif 
(PDB (6M0J).
MAb production and purification
Sequences of mAbs that had been synthesized (Twist Bioscience) and 
cloned into an IgG1 monocistronic expression vector (designated as 
pTwist-mCis_G1) were used for mammalian cell culture mAb secretion. 
This vector contains an enhanced 2A sequence and GSG linker that 
allows simultaneous expression of mAb heavy and light chain genes 
from a single construct upon transfection53. We previously described 
microscale expression of mAbs in 1 mL ExpiCHO cultures in 96-well 
plates5. For larger scale mAb expression, we performed transfection 
(1 to 300 mL per antibody) of CHO cell cultures using the Gibco™ Expi-
CHO™ Expression System and protocol for 50 mL mini bioreactor tubes 
(Corning) as described by the vendor. Culture supernatants were puri-
fied using HiTrap MabSelect SuRe (Cytiva, formerly GE Healthcare Life 
Sciences) on a 24-column parallel protein chromatography system 
(Protein BioSolutions). Purified mAbs were buffer-exchanged into 
PBS, concentrated using Amicon® Ultra-4 50KDa Centrifugal Filter 
Units (Millipore Sigma) and stored at 4 °C until use. Purified mAbs were 
tested routinely for endotoxin levels that found to be <30 EU/mg IgG 
for mouse studies and <1 EU/mg IgG for NHP studies. Endotoxin test-
ing was performed using the PTS201F cartridge (Charles River), with 
sensitivity range from 10 to 0.1 EU/mL, and an Endosafe Nexgen-MCS 
instrument (Charles River).
ELISA binding assays
Wells of 96-well microtiter plates were coated with purified recom-
binant SARS-CoV-2 S protein or SARS-CoV-2 SRBD protein at 4 °C over-
night. Plates were blocked with 2% non-fat dry milk and 2% normal 
goat serum in DPBS containing 0.05% Tween-20 (DPBS-T) for 1 hr. The 
bound antibodies were detected using goat anti-human IgG conju-
gated with HRP (horseradish peroxidase) (Southern Biotech, Cat# 
2040-05, Lot B3919-XD29, 1:5,000 dilution) and TMB (3,3′,5,5′-tetra
methylbenzidine) substrate (Thermo Fisher Scientific). Color devel-
opment was monitored, 1 N hydrochloric acid was added to stop the 
reaction, and the absorbance was measured at 450 nm using a spec-
trophotometer (Biotek). For dose-response assays, serial dilutions of 
purified mAbs were applied to the wells in triplicate, and mAb binding 
was detected as detailed above. Half-maximal effective concentration 
(EC50) values for binding were determined using Prism v8.0 software 
(GraphPad) after log transformation of mAb concentration using 
sigmoidal dose-response nonlinear regression analysis.
RBD minimal hACE2 recognition motif peptide binding ELISA
Wells of 384-well microtiter plates were coated with 1 µg/mL strepta-
vidin at 4 °C overnight. Plates were blocked with 0.5% BSA in DPBS 
containing 0.05% Tween-20 (DPBS-T) for 1 hr. Plates were washed 4x 
with 1x PBST and 2 µg/mL biotinylated-ACE2 binding motif peptide (cat. 
# LT5578, from LifeTein, LLC) was added to bind streptavidin for 1 hr at 
ambient temperature. Purified mAbs were diluted in blocking buffer, 
added to the wells, and incubated for 1 hr at ambient temperature. The 
bound antibodies were detected using goat anti-human IgG conjugated 
with HRP (horseradish peroxidase) (cat. # 2014-05, Southern Biotech) 
and TMB (3,3′,5,5′-tetramethylbenzidine) substrate (ThermoFisher 
Scientific). Color development was monitored, 1N hydrochloric acid 
was added to stop the reaction, and the absorbance was measured 
at 450 nm using a spectrophotometer (Biotek). For dose-response 
assays, serial 3-fold dilutions starting at 10 µg/mL concentration of 
purified mAbs were applied to the wells in triplicate, and mAb binding 
was detected as detailed above.
Analysis of binding of antibodies to variant RBD proteins with 
alanine or arginine point mutations
Biolayer light interferometry (BLI) was performed using an Octet RED96 
instrument (ForteBio; Pall Life Sciences) and wild-type RBD protein or 
a mutant RBD protein with a single amino acid change at defined posi-
tions to alanine or arginine. Binding of the RBD proteins were confirmed 
by first capturing octa-His-tagged RBD wild-type or mutant protein 
from a 10 µg/mL (≈200 nM) solution onto Penta-His biosensors for 
300 sec. The biosensor tips then were submerged in binding buffer 
(PBS/0.2% Tween 20) for a 60 sec wash, followed by immersion in a 
solution containing 150 nM of mAb for 180 sec (association), followed 
by a subsequent immersion in binding buffer for 180 sec (dissociation). 
Response for each RBD mutant protein was normalized to that of the 
wild-type RBD protein.
Focus reduction neutralization test (FRNT)
Serial dilutions of mAbs were incubated with 102 FFU of SARS-CoV-2 for 1 
hr at 37 °C. The mAb–virus complexes were added to Vero E6 cell culture 
monolayers in 96-well plates for 1 hr at 37 °C. Subsequently, cells were 
overlaid with 1% (w/v) methylcellulose in Minimum Essential Medium 
(MEM) supplemented to contain 2% heat-inactivated FBS. Plates were 
fixed 30 hrs later by removing overlays and fixed with 4% PFA in PBS for 
20 min at room temperature. The plates were incubated sequentially 
with 1 µg/mL of rCR3022 anti-S antibody12 and horseradish-peroxidase 
(HRP)-conjugated goat anti-human IgG (Sigma-Aldrich, Cat# A6029) 
in PBS supplemented with 0.1% (w/v) saponin (Sigma) and 0.1% bovine 
serum albumin (BSA). SARS-CoV-2-infected cell foci were visualized 
using TrueBlue peroxidase substrate (KPL) and quantitated on an Immu-
noSpot 5.0.37 Macro Analyzer (Cellular Technologies). Data were pro-
cessed using Prism software version 8.0 (GraphPad). IC50 values were 
determined by nonlinear regression analysis using the Prism software.
Generation of S protein pseudotyped lentivirus
Suspension cultures of 293 cells were seeded and transfected with a 
third-generation HIV-based lentiviral vector expressing luciferase along 
with packaging plasmids encoding for the following: SARS-CoV-2 spike 
protein with a C-terminal 19 amino acid deletion, Rev, and Gag-pol. 
Medium was changed 16 to 20 hrs after transfection, and the super-
natant containing virus was harvested 24 hrs later. Cell debris was 
removed by low-speed centrifugation, and the supernatant was passed 
through a 0.45 µm filter unit. The pseudovirus was pelleted by ultracen-
trifugation and resuspended in PBS for a 100-fold concentrated stock.
Pseudovirus neutralization assay
Serial dilutions of mAbs were prepared in a 384-well microtiter plate 
and pre-incubated with pseudovirus for 30 minutes at 37 °C, to which 
293 cells that stably express human ACE2 were added. The plate was 
returned to the 37 °C incubator, and then 48 hrs later luciferase activity 
measured on an EnVision 2105 Multimode Plate Reader (Perkin Elmer) 
using the Bright-Glo™ Luciferase Assay System (Promega), according to 
manufacturer’s recommendations. Percent inhibition was calculated 
relative to pseudovirus-alone control. IC50 values were determined by 
nonlinear regression using the Prism software version 8.1.0 (Graph-
Pad). The average IC50 value for each antibody was determined from a 
minimum of 3 independent experiments.
Measurement of synergistic neutralization by an antibody 
combination
Synergy was defined as higher neutralizing activity mediated by a 
cocktail of two mAbs when compared to that mediated by individual 
mAbs at the same total concentration of antibodies in vitro. To assess 
if two mAbs synergize in a cocktail to neutralize SARS-CoV-2, we used 
a previously reported approach to quantitate synergy11. To evaluate 














observed combination responses (dose-response matrix) were com-
pared with the expected responses calculated by means of synergy scor-
ing models11. Virus neutralization was measured in a conventional focus 
reduction neutralization test (FRNT) assay using wild-type SARS-CoV-2 
and Vero E6 cell culture monolayers. Individual mAbs COV2-2196 and 
COV2-2130 were mixed at different concentrations to assess neutraliz-
ing activity of different ratios of mAbs in the cocktail. Specifically, each 
of seven-fold dilutions of mAb COV2-2130 (starting from 500 ng/mL) 
was mixed with each of the nine dilutions of mAb COV2-2196 (starting 
from 500 ng/mL) in a total volume of 50 µL of per each condition and 
then incubated with 50 µL of live SARS-CoV-2 in cell culture medium 
(RPMI-1640 medium supplemented with 2% FBS) before applying to 
confluent Vero E6 cells grown in 96-well plates. The control values 
included those for determining dose-response of the neutralizing 
activity measured separately for the individual mAb COV2-2196 or 
COV2-2130, which were assessed at the same doses as in the cocktail. 
Each measurement was performed in duplicate. We next calculated 
percent virus neutralization for each condition and then calculated the 
synergy score value, which defined interaction between these two mAbs 
in the cocktail. A synergy score of less than -10 indicates antagonism, 
a score from -10 to 10 indicates an additive effect, and a score greater 
than 10 indicates a synergistic effect11.
MAb quantification
Quantification of purified mAbs was performed by UV spectropho-
tometry using a NanoDrop spectrophotometer and accounting for 
the extinction coefficient of human IgG.
Competition-binding analysis through biolayer interferometry
Anti-mouse IgG Fc capture biosensors (FortéBio 18-5089) on an Octet 
HTX biolayer interferometry instrument (FortéBio) were soaked for 10 
minutes in 1x kinetics buffer (Molecular Devices 18-1105), followed by a 
baseline signal measurement for 60 seconds. Recombinant SARS-CoV-2 
RBD fused to mouse IgG1 (RBD-mFc, Sino Biological 40592-V05H) was 
immobilized onto the biosensor tips for 180 seconds. After a wash 
step in 1x kinetics buffer for 30 seconds, the reference antibody (5 
µg/mL) was incubated with the antigen-containing biosensor for 600 
seconds. Reference antibodies included the SARS-CoV human mAb 
CR3022 and COV2-2196. After a wash step in 1x kinetics buffer for 30 sec-
onds, the biosensor tips then were immersed into the second antibody 
(5 µg/mL) for 300 seconds. Maximal binding of each antibody was nor-
malized to a buffer-only control. Self-to-self blocking was subtracted. 
Comparison between the maximal signal of each antibody was used 
to determine the percent binding of each antibody. A reduction in 
maximum signal to <33% of un-competed signal was considered full 
competition of binding for the second antibody in the presence of the 
reference antibody. A reduction in maximum signal to between 33 to 
67% of un-competed was considered intermediate competition of bind-
ing for the second antibody in the presence of the reference antibody. 
Percent binding of the maximum signal >67% was considered absence 
of competition of binding for the second antibody in the presence of 
the reference antibody.
hACE2 inhibition analysis
Wells of 384-well microtiter plates were coated with purified recombi-
nant SARS-CoV-2 S2Pecto protein at 4 °C overnight. Plates were blocked 
with 2% non-fat dry milk and 2% normal goat serum in DPBS-T for 1 hr. 
For screening assays, purified mAbs from microscale expression were 
diluted two-fold in blocking buffer starting from 10 µg/mL in tripli-
cate, added to the wells (20 µL/well), and incubated for 1 hr at ambient 
temperature. Recombinant human ACE2 (hACE2) with a C-terminal 
FLAG tag peptide was added to wells at 2 µg/mL in a 5 µL/well volume 
(final 0.4 µg/mL concentration of hACE2) without washing of anti-
body and then incubated for 40 min at ambient temperature. Plates 
were washed, and bound hACE2 was detected using HRP-conjugated 
anti-FLAG antibody (Sigma-Aldrich Cat# A8592, Lot SLBV3799, 1:5,000 
dilution) and TMB substrate. ACE2 binding without antibody served as 
a control. The signal obtained for binding of the hACE2 in the presence 
of each dilution of tested antibody was expressed as a percentage of 
the hACE2 binding without antibody after subtracting the background 
signal. For dose-response assays, serial dilutions of purified mAbs were 
applied to the wells in triplicate, and mAb binding was detected as 
detailed above. Half-maximal inhibitory concentration (IC50) values for 
inhibition by mAb of S2Pecto protein binding to hACE2 was determined 
after log transformation of antibody concentration using sigmoidal 
dose-response nonlinear regression analysis (Prism software, GraphPad 
Prism version 8.0).
hACE2 blocking assay using biolayer interferometry biosensor
Anti-mouse IgG biosensors on an Octet HTX biolayer interferom-
etry instrument (FortéBio) were soaked for 10 min in 1x kinetics 
buffer, followed by a baseline signal measurement for 60 seconds. 
Recombinant SARS-CoV-2 RBD fused to mouse IgG1 (RBD-mFc, Sino 
Biological 40592-V05H) was immobilized onto the biosensor tips for 
180 sec. After a wash step in 1x kinetics buffer for 30 sec, the antibody 
(5 µg/mL) was incubated with the antigen-coated biosensor for 600 sec. 
After a wash step in 1x kinetics buffer for 30 sec, the biosensor tips then 
were immersed into the hACE2 receptor (20 µg/mL) (Sigma-Aldrich 
SAE0064) for 300 sec. Maximal binding of hACE2 was normalized 
to a buffer-only control. Percent binding of hACE2 in the presence of 
antibody was compared to hACE2 maximal binding. A reduction in 
maximal signal to <30% was considered hACE2 blocking.
High-throughput competition-binding analysis
Wells of 384-well microtiter plates were coated with purified SARS-CoV-2 
S2Pecto protein at 4 °C overnight. Plates were blocked with 2% BSA in 
DPBS containing 0.05% Tween-20 (DPBS-T) for 1 hr. Micro-scale puri-
fied unlabeled mAbs were diluted ten-fold in blocking buffer, added 
to the wells (20 µL/well) in quadruplicates, and incubated for 1 hr at 
ambient temperature. A biotinylated preparation of a recombinant 
mAb based on the variable gene sequence of the previously described 
mAb CR302212 and also newly identified mAbs COV2-2096, -2130, and 
-2196 that recognized distinct antigenic regions of the SARS-CoV-2 
S protein were added to each of four wells with the respective mAb 
at 2.5 µg/mL in a 5 µL/well volume (final 0.5 µg/mL concentration of 
biotinylated mAb) without washing of unlabeled antibody and then 
incubated for 1 hr at ambient temperature. Plates were washed, and 
bound antibodies were detected using HRP-conjugated avidin (Sigma) 
and TMB substrate. The signal obtained for binding of the biotin-labeled 
reference antibody in the presence of the unlabeled tested antibody
was expressed as a percentage of the binding of the reference antibody 
alone after subtracting the background signal. Tested mAbs were con-
sidered competing if their presence reduced the reference antibody 
binding to less than 41% of its maximal binding and non-competing 
if the signal was greater than 71%. A level of 40–70% was considered 
intermediate competition.
Plasma or serum antibody competition-binding assays
Wells of 384-well microtiter plates were coated with purified 
SARS-CoV-2 S2Pecto at 4 °C overnight. Plates were blocked with 2% BSA 
in DPBS-T for 1 hr. Plasma or serum samples were diluted in blocking 
buffer two-fold starting from 1:10 sample dilution, added to the wells 
(20 µL/well) in triplicate, and incubated for 1 hr at ambient tempera-
ture. For self-blocking controls, unlabeled mAbs COV2-2096 or COV2-
2130 were added at 10 µg/mL to separate wells coated with S2Pecto. 
Serum from a donor without an exposure history to SARS-CoV-2 was 
used as a negative control for mAb binding inhibition. A biotinylated 
mAb COV2-2096 or COV2-2130 was added to the respective wells at 
2.5 µg/mL in a 5 µL/well volume (final 0.5 µg/mL concentration of 














incubated for 30 min at ambient temperature. Binding of biotinylated 
mAbs COV2-2096 or COV2-2130 alone to S2Pecto served as a control 
for maximal binding. Plates were washed, and bound antibodies were 
detected using HRP-conjugated avidin (Sigma) and TMB substrate. 
Inhibition of COV2-2096 or COV2-2130 binding in the presence of 
each dilution of tested plasma or serum was calculated as a percent 
of maximal COV2-2096 or COV2-2130 binding inhibition using values 
from COV2-2096 or COV2-2130 binding alone (maximal binding) and 
the corresponding self-blocking controls (maximal inhibition) after 
subtracting the background signal. For hACE2 inhibition assay by 
plasma or serum antibodies, plasma or serum samples were diluted 
and added to wells with S2Pecto as detailed above. Recombinant human 
hACE2 was added to wells at 2 µg/mL in a 5 µL/well volume (final 
0.4 µg/mL concentration of hACE2) without washing of antibody and 
then incubated for 40 min at ambient temperature. Plates were washed, 
and bound hACE2 was detected using HRP-conjugated anti-FLAG anti-
body (Sigma) and TMB substrate. hACE2 binding without antibody 
served as a control. The signal obtained for binding of the hACE2 in the 
presence of each dilution of tested plasma or serum was expressed as 
a percentage of the ACE2 binding without antibody after subtracting 
the background signal.
Binding analysis of mAbs to alanine or arginine RBD mutants
Biolayer light interferometry was performed using an Octet RED96 
instrument (FortéBio; Pall Life Sciences). Binding was confirmed by 
first capturing octa-His-tagged RBD mutants 10 µg/mL (≈200 nM) 
onto Penta-His biosensors for 300 sec. The biosensors then were sub-
merged in binding buffer (PBS/0.2% TWEEN 20) for a wash for 60 sec 
followed by immersion in a solution containing 150 nM of mAbs for 
180 sec (association), followed by a subsequent immersion in binding 
buffer for 180 sec (dissociation). Response for each RBD mutant was 
normalized to that of wild-type RBD.
Protection against authentic SARS-CoV-2 in human 
hACE2-transduced mice
Animal studies were carried out in accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocols were approved by the Insti-
tutional Animal Care and Use Committee at the Washington University 
School of Medicine (assurance number A3381–01). Virus inoculations 
were performed under anesthesia that was induced and maintained 
with ketamine hydrochloride and xylazine, and all efforts were made 
to minimize animal suffering.
Wild-type, female BALB/c mice were purchased from Jackson Labora-
tories (strain 000651). Animals were housed in groups of up to 5 mice/
cage at 18-24 °C ambient temperatures and 40-60% humidity. Mice 
were fed a 20% protein diet (PicoLab 5053, Purina) and maintained on 
a 12 hour light/dark cycle (6 am to 6 pm). Food and water were avail-
able ad libitum.
Mice (10-11-week-old) were given a single intraperitoneal injection 
of 2 mg of anti-Ifnar1 mAb (MAR1-5A354, Leinco) one day before intra-
nasal administration of 2.5 x 108 PFU of AdV-hACE2. Five days after AdV 
transduction, mice were inoculated with 4 x 105 PFU of SARS-CoV-2 by 
the intranasal route. Anti-SARS-CoV-2 human mAbs or isotype control 
mAbs were administered 24 hrs prior (prophylaxis) or 12 hrs after (ther-
apy) SARS-CoV-2 inoculation. Weights were monitored on a daily basis, 
and animals were sacrificed at 2 or 7 dpi, and tissues were harvested.
Measurement of viral burden
For RT-qPCR tissues were weighed and homogenized with zirconia 
beads in a MagNA Lyser instrument (Roche Life Science) in 1 ml of 
DMEM media supplemented with 2% heat-inactivated FBS. Tissue 
homogenates were clarified by centrifugation at 10,000 rpm for 
5 min and stored at −80 °C. RNA was extracted using MagMax mirVana 
Total RNA isolation kit (Thermo Scientific) and a Kingfisher Flex 96 
well extraction machine (Thermo Scientific). TaqMan primers were 
designed to target a conserved region of the N gene using SARS-CoV-2 
(MN908947) sequence as a guide (L Primer: ATGCTGCAATCGTGCTA 
CAA; R primer: GACTGCCGCCTCTGCTC; probe: /56-FAM/TCAAGGAAC/
ZEN/AACATTGCCAA/3IABkFQ/). To establish an RNA standard curve, 
we generated concatenated segments of the N gene in a gBlocks frag-
ment (IDT) and cloned this into the PCR-II topo vector (Invitrogen). The 
vector was linearized, and in vitro T7-DNA-dependent RNA transcription 
was performed to generate materials for a quantitative standard curve.
For plaque assay, homogenates were diluted serially 10-fold and 
applied to Vero-furin cell monolayers in 12-well plates. Plates were incu-
bated at 37 °C for 1 hr with rocking every 15 min. Subsequently, cells were 
overlaid with 1% (w/v) methylcellulose in MEM supplemented with 2% 
FBS. Plates were harvested 72 hrs later by removing overlays and fixed 
with 4% PFA in PBS for 20 min at ambient temperature. After removing 
the 4% PFA, plaques were visualized by adding 1 mL/well 0.05% crystal 
violet in 20% methanol for 20 min at ambient temperature. Excess 
crystal violet was washed away with PBS, and plaques were counted.
Cytokine and chemokine mRNA measurements
RNA was isolated from lung homogenates at 7 dpi as described 
above. cDNA was synthesized from DNase-treated RNA using the 
High-Capacity cDNA Reverse Transcription kit (Thermo Scientific) 
with the addition of RNase inhibitor, following the manufacturer’s 
protocol. Cytokine and chemokine expression was determined using 
TaqMan Fast Universal PCR master mix (Thermo Scientific) with com-
mercial primers/probe sets specific for IFNγ (IDT: Mm.PT.58.41769240), 
IL6 (Mm.PT.58.10005566), CXCL10 (Mm.PT.58.43575827), CCL2 (Mm.
PT.58.42151692 and results were normalized to GAPDH (Mm.PT.39a.1) 
levels. Fold change was determined using the 2-ΔΔCt method compar-
ing anti-SARS-CoV-2 specific or isotype control mAb-treated mice to 
naïve controls.
Histology
Animals were euthanized, and tissues were harvested before lung infla-
tion and fixation. The left lung lobe was tied off at the left main bronchus 
and collected for viral RNA analysis. The right lung lobe was inflated 
with ~1.2 mL of 10% neutral buffered formalin using a 3-mL syringe and 
catheter inserted into the trachea. For fixation after infection, inflated 
lungs were kept in a 40-mL suspension of neutral buffered formalin for 
7 days before further processing. Tissues were embedded in paraffin, 
and sections were stained with hematoxylin and eosin. Tissue sections 
were visualized using a Leica DM6B microscope equipped with a Leica 
DFC7000T camera. The sections were scored by an immunopathology 
expert blinded to the compositions of the groups.
Viral challenge studies using MA-SARS-CoV-2 and wild-type mice
Animal studies were carried out in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals of 
the National Institutes of Health. The protocols were approved by the 
Institutional Animal Care and Use Committee at the UNC Chapel Hill 
School of Medicine (NIH/PHS Animal Welfare Assurance Number is 
D16-00256 (A3410-01)). Virus inoculations were performed under anes-
thesia that was induced and maintained with ketamine hydrochloride 
and xylazine, and all efforts were made to minimize animal suffering.
Protection against MA-SARS-CoV-2 in wild-type mice
12-month-old BALB/c mice from Envigo were used in experiments. 
Animals were housed in groups of up to 5 mice/cage at 18-24 °C ambi-
ent temperatures and 40-60% humidity. Mice were fed a 20% protein 
diet (PicoLab 5053, Purina) and maintained on a 12 hrs light/dark cycle 
(8 am to 8 pm). Food and water were available ad libitum. Mice were 
acclimated in the BSL3 for at least 72 hrs prior to start of experiments. At 
6 hrs prior to infection, mice were treated with 200 µg of human mAbs 














a mixture of ketamine and xylazine and intranasally inoculated with 105 
PFU of MA-SARS-CoV-2 diluted in PBS. Daily weight loss was measured, 
and at two days post-infection mice were euthanized by isoflurane 
overdose prior to tissue harvest. For the post-exposure therapy study, 
mice were inoculated via the i.n. route with 105 PFU of MA-SARS-CoV-2 
and 12 hrs later given the indicated antibody treatments by i.p. injec-
tion. The lungs were harvested at 2 dpi.
Plaque assay of lung tissue homogenates
The lower lobe of the right lung was homogenized in 1 mL PBS using a 
MagnaLyser (Roche). Serial dilutions of virus were titered on Vero E6 
cell culture monolayers, and virus plaques were visualized by neutral 
red staining at two days after inoculation. The limit of detection for 
the assay is 100 PFU per lung.
NHP challenge study
The NHP research studies adhered to principles stated in the eighth 
edition of the Guide for the Care and Use of Laboratory Animals. The 
facility where this research was conducted (Bioqual Inc., Rockville, MD) 
is fully accredited by the Association for Assessment and Accreditation 
of Laboratory Animal Care International (AAALAC) and approved by 
the Office of Laboratory Animal Welfare (NIH/PHS Assurance ID: D16-
00052). NHP studies were conducted in compliance with all relevant 
local, state, and federal regulations and were approved by the Animal 
Care and Use Committee (IACUC) at Bioqual. NHP studies were con-
ducted in compliance with all relevant local, state, and federal regula-
tions and were approved by the relevant Institutional Animal Care and 
Use Committee (IACUC) at Bioqual Inc.
Twelve healthy adult rhesus macaques (Macaca mulatta) of Indian 
origin (5 to 15 kg body weight) were studied. Rhesus macaques were 
5-7 years old and mixed male and female. Animals were allocated ran-
domly to two anti-SARS-CoV-2 mAb treatment groups (n=4 per group) 
and one control (isotype-treated) group (n=4 per group). Animals 
received one 50 mg/kg dose of mAb COV2-2196 or mAb COV2-2381 or 
isotype control mAb intravenously on day -3 and then were challenged 
in three days with 1.1 × 104 PFU SARS-CoV-2, administered as 1 mL by 
the i.n route and 1 mL by the intratracheal route. Following challenge, 
viral RNA was assessed by RT-qPCR in bronchoalveolar lavage and nasal 
swabs at multiple time points as described34,35. All animals were given 
physical examinations. In addition, all animals were monitored daily 
with an internal scoring protocol approved by the Institutional Animal 
Care and Use Committee. These studies were not blinded.
Detection of circulating human mAbs in NHP serum
ELISA plates were coated overnight at 4 °C with 1 µg/mL of goat 
anti-human IgG (H+L) secondary antibody (monkey pre-adsorbed) 
(Novus Biologicals, Cat# NB7487) and then blocked for 2 hrs. The serum 
samples were assayed at 3-fold dilutions starting at a 1:3 dilution in 
Blocker Casein in PBS (ThermoFisher) diluent. Samples were incu-
bated for 1 hr at ambient temperature and then removed, and plates 
were washed. Wells then were incubated for 1 hr with HRP-conjugated 
goat anti-Human IgG (monkey pre-adsorbed) (Southern Biotech Cat# 
2049-05) at a 1:4,000 dilution. Wells were washed and then incubated 
with SureBlue Reserve TMB Microwell Peroxidase Substrate (Seracare) 
(100 µL/well) for 3 min followed by TMB Stop Solution (Seracare) to 
stop the reaction (100 µL/well). Microplates were read at 450 nm. The 
concentrations of the human mAbs were interpolated from the linear 
range of purified human IgG (Sigma) standard curves using Prism soft-
ware, version 8.0 (GraphPad).
Quantification and statistical analysis
The descriptive statistics mean ± SEM or mean ± SD were determined 
for continuous variables as noted. Technical and biological repli-
cates are described in the figure legends. In the mouse studies, the 
comparison of weight change curves was performed using repeated 
measurements two-way ANOVA with Tukey's post-test using Prism 
v8.0 (GraphPad). Viral burden and gene expression measurements 
were compared using Kruskal-Wallis ANOVA with Dunn’s post-test or 
two-sided Mann-Whitney U test using Prism v8.0 (GraphPad). Synergy 
score and dose-response matrix analysis were performed using a web 
application SynergyFinder28.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
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ognition motif (PDB (6M0J) are publicly available. Sequences of mAbs 
characterized here are available from GenBank under the following 
accession numbers: MT665032 - MT665070, MT665419 - MT665457, 
MT665138, and MT665525. Materials reported in this study will be made 
available but may require execution of a Materials Transfer Agree-
ment. Source data are provided with this paper.
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Extended Data Fig. 1 | SARS-CoV-2 neutralization curves for mAb panel. Neutralization of authentic SARS-CoV-2 by human mAbs. Mean ± SD of technical 














Extended Data Fig. 2 | Inhibition curves for mAb inhibition of S2Pecto binding to hACE2. Blocking of hACE2 binding to S2Pecto by anti-SARS-CoV-2 neutralizing 













Extended Data Fig. 3 | ELISA binding of anti-SARS-CoV-2 neutralizing human mAbs to trimeric SRBD, S2Pecto, or SARS-CoV S2Pecto antigen. Mean ± SD of 













Extended Data Fig. 4 | Serum or plasma mAbs competition binding.  
a. Inhibition of hACE2 binding to S2Pecto by serum or plasma of four SARS-CoV-2 
immune subjects or one non-immune control in ELISA using SARS-CoV-2 
S2Pecto. mAbs were isolated from subjects 3 and 4 as described previously
5. 
Mean ± SD of triplicates of one experiment is shown. Dotted line indicates full 
inhibition (100%) of hACE2 by 500 ng/mL of control mAb COV2-2196 or 
COV2-2130. b. Inhibition of mAb COV2-2130 (left) or COV2-2196 (right) binding 
to S2Pecto by serum or plasma of four SARS-CoV-2 immune subjects or one 
non-immune control in ELISA using SARS-CoV-2 S2Pecto. Mean ± SD of triplicates 
and representative of two experiments are shown. Dotted line indicates 
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Internal Trimer Face External Trimer Face 
COV2-2094 
Extended Data Fig. 5 | Mapping of mAb critical contact residues by alanine 
and arginine mutagenesis and biolayer interferometry. a. Bar graphs show 
response values for mAb binding to wt or mutant SRBD constructs normalized  
to wt. Asterisks denote residues where increased dissociation of mAb was 
observed, likely indicating the residue is proximal to mAb epitope. Full 
response curves for mAb association and dissociation with wt or mutant SRBD 
constructs are also shown. b. Structure of the RBD highlighting the critical 














Extended Data Fig. 6 | Sequence features of human mAbs used in animal 
studies and mAb pharmacokinetics following infusion in NHPs. a. Sequence 
features of human mAbs tested in animal models. Inferred variable genes are 
indicated and CDR3 amino acids are shown for heavy and light chains. b. NHPs 
received one 50 mg/kg dose of mAb COV2-2196, COV2-2381, or isotype control 
mAb (n = 4 animals per group) intravenously on day -3 and then were challenged 
intranasally and intratracheally with SARS-CoV-2 at day 0. Concentration of 
human mAbs was determined at indicated timepoints. Each curve shows an 
individual animal. Data represent a single experiment.
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